Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Levodopa-induced dyskinesia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Levodopa-induced dyskinesia. Displaying page 1 of 1.
    EudraCT Number: 2020-006004-16 Sponsor Protocol Number: 03PDE2020 Start Date*: 2021-07-16
    Sponsor Name:Celon Pharma S.A.
    Full Title: Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Diseas...
    Medical condition: Levodopa-induced dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022517-25 Sponsor Protocol Number: ADX48621-201 Start Date*: 2011-05-30
    Sponsor Name:Addex Pharma SA
    Full Title: Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesi...
    Medical condition: Levodopa induced dyskinesia in Parkinson's disease patients
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002467-27 Sponsor Protocol Number: 2007 Neuro 12 Start Date*: 2008-01-24
    Sponsor Name:Salford Royal NHS Foundation Trust
    Full Title: Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias
    Medical condition: Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    13.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    13.1 10029205 - Nervous system disorders 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003739-20 Sponsor Protocol Number: ADS-AMT-PD302 Start Date*: 2015-04-23
    Sponsor Name:Adamas Pharmaceuticals, Inc.
    Full Title: Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia
    Medical condition: Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003738-24 Sponsor Protocol Number: ADS-AMT-PD304 Start Date*: 2015-04-23
    Sponsor Name:Adamas Pharmaceuticals, Inc.
    Full Title: ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia
    Medical condition: Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-006053-22 Sponsor Protocol Number: NLX-112-DYS-101 Start Date*: 2021-09-22
    Sponsor Name:Neurolixis SAS
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease
    Medical condition: Parkinson´s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000373-13 Sponsor Protocol Number: AMBS-ELTO-201 Start Date*: 2015-08-18
    Sponsor Name:Amarantus BioScience Holdings, Inc.
    Full Title: Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatmen...
    Medical condition: Parkinson’s disease levodopa induced dyskinesia (PD-LID)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-005422-35 Sponsor Protocol Number: Start Date*: 2015-05-28
    Sponsor Name:Imperial College London-Imperial College Healthcare NHS Trust
    Full Title: THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO.
    Medical condition: Levodopa induced dyskinesias within Parkinson's disease.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017174-20 Sponsor Protocol Number: EMR701165_023 Start Date*: 2010-03-15
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering...
    Medical condition: Idiopathic Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001131-36 Sponsor Protocol Number: OS320-3005 Start Date*: 2014-10-23
    Sponsor Name:Osmotica Pharmaceutical Corp.
    Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodo...
    Medical condition: Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-001132-10 Sponsor Protocol Number: OS320-3006 Start Date*: 2014-10-23
    Sponsor Name:Osmotica Pharmaceutical Corp.
    Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodo...
    Medical condition: Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019418-25 Sponsor Protocol Number: CAFQ056A2217 Start Date*: 2010-07-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias
    Medical condition: pazienti con malattia di Parkinson con discinesie indotte dalla L-dopa.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043118 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008712-98 Sponsor Protocol Number: CAFQ056A2208 Start Date*: 2009-05-18
    Sponsor Name:Novartis Pharma AG
    Full Title: 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...
    Medical condition: moderate to severe levodopa induced dyskinesias in patients with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013916 Dyskinesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015928-28 Sponsor Protocol Number: ELTODYS09 Start Date*: 2010-10-07
    Sponsor Name:PsychoGenics Inc
    Full Title: A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease...
    Medical condition: Dyskinesias related to levodopa treatment in Parkinson´s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000135-14 Sponsor Protocol Number: PXT-CL17-001 Start Date*: 2017-05-26
    Sponsor Name:Prexton Therapeutics B.V.
    Full Title: A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in ...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002254-70 Sponsor Protocol Number: 6002-014 Start Date*: 2014-02-28
    Sponsor Name:Kyowa Kirin Pharmaceutical Development, Inc.
    Full Title: A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Sever...
    Medical condition: Moderate to severe Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    19.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002937-20 Sponsor Protocol Number: E2007-G000-309 Start Date*: 2006-12-11
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) IT (Completed) FR (Completed) ES (Completed) HU (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 15:08:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA